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Thirty-three patients with sustained ventricular arrhyth-
mias underwent electrophysiologic testing after intra-
venous and again after oral procainamide administra-
tion. Two groups were identified: group 1 included 15
patients with concordant serum procainamide concen-
trations with less than a 3 JLg/ml difference after intra-
venous (mean 8.6 ± 2.7) and oral (mean 8.8 ± 2.7)
procainamide administration, with mean N-acetylpro-
cainamide concentrations of 1.0 ± 0.6 and 6.2 ± 2.8
JLg/ml, respectively. Group 2 included 18 patients with
discordant serum procainamide concentrations after in-
travenous (mean 9.5 ± 5.9 JLg/ml) and oral (mean 14.1
± 5.2 JLg/ml) procainamide, with mean N-acetylpro-
cainamide concentrations of 0.9 ± 0.5 and 10.7 ± 5.7
JLg/ml, respectively.
In group 1, response to programmed stimulation was
the same after intravenous and oral procainamide
administration, with no inducible ventricular arrhyth-
mia in 5 of 15 patients. In group 2, 3 of 18 patients had
no inducible arrhythmia after intravenous compared with
7 of 18 patients after oral procainamide administration.
There was a different response to programmed stimu-
lation after oral compared with intravenous procain-
Procainamide has been used for more than 30 years to pre-
vent life-threatening ventricular arrhythmias (1-4). Re-
centl y. programmed ventricular stimulation has proved ef-
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amide in 6 of 18 patients in group 2 but in none of 15
patients in group 1 (p = 0.02). The effective procain-
amide concentration was greater than the ineffective
concentration in fiveof the six patients with a discordant
response, and the effective route of administration was
oral in five of the six patients. The change in ventricular
refractoriness in group 1 was similar after intravenous
(28 ± 23 ms) and oral (29 ± 19 ms) procainamide,
whereas in group 2, refractoriness was increased more
after oral (33 ± 21 ms) than intravenous (20 ± 17 ms)
procainamide administration and paralleled the differ-
ence in procainamide concentration.
In conclusion, intravenous procainamide closely pre-
dicts the electrophysiologiceffects of oral procainamide
when similar serum procainamide concentrations are
achieved, and N-acetylprocainamide contributes little to
the electrophysiologic effects of procainamide at the ob-
served concentrations. If intravenous procainamide fails
to prevent ventricular arrhythmia induction, repeat test-
ing to determine the effect of oral therapy appears to be
indicated only if increased procainamide serum concen-
trations of at least greater than 3 JLg/ml can be achieved.
fective in evaluating the ability of procainamide and other
type IA antiarrhythmic agents to prevent sustained ventric -
ular arrhythmias (5-7), Short-term intravenous administra-
tion of procainamide has been used dur ing electrophysio-
logic study to allow for the rapid assessment of the
antiarrhythmic efficacy of this agent. It has been presumed
that intravenous and oral administration will cause similar
electrophysiologic effects . However, correlation of the an-
tiarrh ythm ic effect of intravenous and oral procainamide has
not been carefully assessed. The need to repeat programmed
stimulation after the oral administration of procainamide is
unkno wn . The purpo se of this stud y was to determine if
intravenous procainamide predicted electrophys iologic ef-
fects of oral procainamide in patients with sustained ven-
tricular arrhythmias.
0735-1097/84/$3.00
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Methods
Study patients. There Were 26 men and 7 women (rang-
ing in age from 23 to 78 years) in the study group. Twenty-
eight patients had coronary artery disease , three had idio-
pathic congestive cardiomyopathy and two had no docu-
mented structural heart disease.
All patients had either sustained ventricular arrhythmias
reproducibly initiated during programmed stimulation (32
patients) or incessant ventricular tachycardia (I patient) .
Twenty-nine patients had sustained ventricular tachycardia
and three patients had ventricular fibrillation induced during
programmed stimulation. Twenty-two of the patients had
clinically documented episodes of sustained ventricular
tachycardia, eight patients had a cardiac arrest with ven-
tricular fibrillation being the first rhythm documented and
three patients had unexplained syncope.
Electrophysiologic study. Baseline electrophysiologic
studies were performed in the nonsedated postabsorptive
state after all antiarrhythmic drugs were discontinued for at
least five half-lives. Two to five multipolar electrode cath-
eters were introduced percutaneously or by cutdown and
positioned under fluoroscopic guidance in the high right
atrium, atrioventricular (AV) junction, right ventricular apex
and right ventricular outflow tract. Programmed ventricular
stimulation included the introduction of single and double
(10 patients) and triple (23 patients) ventricular extrastimuli
from at least two right ventricular sites during at least two
paced cycle lengths , usually 600 and 400 ms in duration .
In addition, rapid ventricular pacing at cycle lengths from
350 to 250 ms for 5 to 15 seconds was performed. If the
arrhythmia was not initiated with right ventricular stimu-
lation , left ventricular stimulation was also performed using
the same number of extrastimuli as with right ventricular
stimulation. After procainamide administration, the com-
plete stimulation protocol was repeated, including left ven-
tricular stimulation if the latter was required to initiate the
arrhythmia in the baseline state.
Stimulation was performed with a custom designed , pro-
grammable stimulator (Bloom Associates , Ltd.) using a con-
stant current source. Rectangular impulses of I ms duration
were delivered at twice diastolic threshold . Recordings were
made using a 16 channel physiologic recorder (VR-16 , Elec-
tronics for Medicine) and the real time records were obtained
with an Inkjet recorder (Siemens-Elema mingograph) at pa-
per speeds of 100 to 250 mm/s .
The specific electrophysiologic variables assessed before
and after procainamide administration included: I) the ven-
tricular refractory period at comparable cycle length; 2) the
ability to initiate the sustained ventricular arrhythmia; 3) the
mode of induction of sustained ventricular arrhythmia; and
4) the QRS configuration and the cycle length of the induced
ventricular tachycardia.
Definitions. Sustained ventricular tachycardia . Tachy-
cardia lasting more than 30 seconds or requiring termination
by programmed ventricular stimulation or cardioversion be-
fore that time because of hemodynamic collapse.
Morphologically similar ventricular tachycardias . Two
episodes of tachycardia displaying the same bundle branch
block morphologic pattern and a frontal plane axis less than
900 divergent.
Ventricular effective refractory period. The longest
coupling interval (S IS2) of the premature right ventricular
stimulus that does not result in ventricular capture .
Change in inducibility of ventricular arrhythmia. The
ability to initiate the sustained ventricular arrhythmia with
fewer or a greater number of extrastimuli. The ranking sys-
tem for this study progressed from: I) an incessant tachy-
cardia, 2) a tachycardia induced with a single extrastimulus,
3) double extrastimuli, 4) rapid ventricular pacing, or 5)
triple extrastimuli, and 6) a noninducible tachycardia. This
order represents a progression from " easier" to "harder."
Intravenous procainamide administration. Procain-
amide was administered intravenously, 500 to 1,800 mg,
at a rate of 50 mg/min . The dose routinely selected was 15
mg/kg or I g. Selected patients with a history of clinical
recurrence of ventricular tachycardia on a low dose of pro-
cainamide were given a greater loading dose . The mean
procainarnide dose administered was 1,150 ± 120 mg. Blood
pressure was monitored with sphygmomanometry every 5
minutes during the drug infusion . Administration of the total
desired dose of procainamide was restricted by the transient
development of nausea or a significant decline (> 15 mm
Hg) in systolic blood pressure in three patients.
After completion of the bolus infusion, a continuous in-
fusion of procainamide at a dose rate ranging from 2 to 10
mg/min was initiated in an attempt to maintain a stable
serum concentration. No patient had nausea or persistent
significant decrease in blood pressure at the time of pro-
grammed stimulation. In all patients, serum procainamide
and N-acetylprocainamide concentrations were determined
at the completion of the stimulation protocol using a standard
high pressure liquid chromatography method (8). In four
patients, procainamide levels were obtained at the beginning
and the end of the stimulation protocol to determine the
variability in concentrations from the beginning to the end
of the stimulation protocol .
Oral procainamide administration. After 2 to 5 days
of orally administered procainamide, all patients underwent
repeat programmed ventricular stimulation. Procainamide
dosage ranged from 500 to 2,000 mg every 4 hours. The
dosage was selected to achieve a serum concentration at
least equal to that attained intravenously or that which was
maximally tolerated without side effects. All patients under-
went the same stimulation protocol as in the baseline state.
Plasma procainamide and N-acetylprocainamide levels were
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again determined at the completion of the stimulation pro-
tocol. In three patients, procainamide levels were obtained
at the beginning and end of the stimulation protocol.
Statistical analysis. Data are reported as the mean :±:
standarddeviation. Statisticalanalysis was performed using
Student's t test for paired and unpaired data, Fisher's exact
test and linear regression analysiswhenappropriate. A prob-
ability (p) value less than 0.05 was considered statistically
significant. In addition, patients weredivided into two groups
for data analysis. Group I included 15 patients with serum
concentrations after intravenous and oral procainamide
administration within 3 fLg/ml. and group 2 included 18
patients with disparate concentrations of procainamide (sec
later).
Results
Procainamide and N-acetylprocainamide concentra-
tions. The mean procainamide concentration after intra-
venous procainamide administration was 9.1 :±: 4.6 fLg/ml,
with an N-acetylprocainamide level of 1.0 :±: 0.6 fLg/ml.
The mean procainamide concentration after oral procain-
amide administration was 11.7 :±: 4.9 fLg/ml, with an N-
acetylprocainamide concentrationof 8.8 :±: 2.7 fLg/ml. The
procainamide concentration varied by a mean of 1.3 :±: 0.6
fLglmi in the seven patients in whom serum procainamide
levels were obtained at the beginning and at the end of the
stimulation protocol. Because of the measured variability
in serum concentrations during the stimulation protocol and
the fact that steady state serum procainamide concentrations
frequently vary by 3 fLg/ml, serum concentrations of pro-
cainamide after intravenous and oral administration within
3 fLg/ml or just greater than twice the degree in measured
variability were defined as being concordant and those with
greater than 3 fLg/ml difference in concentration as being
discordant (Tables 1 and 2).
Fifteen patients (group 1) had similar serum concentra-
tions after oral (mean 8.8 :±: 2.7 fLg/ml ) and intravenous
(mean 8.6 :±: 2.6 fLg/ml) procainamide administration and
18 patients (group 2) had disimilar procainamide concen-
trationsafter oral (mean 14.1 :±: 5.1 fLg/ml) and intravenous
(mean 9.5 :±: 5.9 fL/ml) procainamide administration . Be-
cause of the study design in which the serum concentration
achieved during oral procainamide administration was at
least that achieved intravenously or that which was tolerated
without side effects, 15 of the 18 patients in group 2 had
greater serum procainamide concentrations after oral ther-
apy. N-acetylprocainamide concentrations were negligible
after intravenous administration in both groups. After orally
administered procainamide, group 1 patients had a meanN-
acetylprocainamide concentration of 6.4 :±: 2.6 fLg/ml and
group 2 patients had a mean N-acetylprocainamide concen-
tration of 10.7 :±: 5.7 fLg/ml.
Effect on inducibility of ventricular tachycardia or
fibrillation. In 13 (39%) of the 33 patients. ventricular
arrhythmias could not be initiated with programmed ven-
tricular stimulation after either intravenous (8 patients) or
oral procainamide (12 patients). The mean serum concen-
tration of procainamide effective in preventing inductionof
the ventricular arrhythmia after intravenous administration
was 10.8 :±: 8.3 fLg/ml. After oral administration of pro-
cainamide, the mean serum concentration effective in pre-
venting induction of the ventriculararrhythmia was 12.0 :±:
4.9 fLglml with a meanN-acetylprocainamide concentration
of 9.5 :±: 4.5 fLg/ml.
Group I versus group 2 patients (Table I) . The ability
to initiate sustained ventricular arrhythmias with pro-
grammed stimulation was the same after intravenous and
oral procainamide administration. Sustained ventricular ar-
rhythmias were not initiated in 5 of 15 patients. In group
2, 8 of 18 patients had no inducible arrhythmias after pro-
cainamide; 7 of 18 patients after oral procainamide admin-
istrationand 3 of 18patients after intravenous procainamide
administration had no inducible arrhythmias. There was a
different response to programmed stimulation after pro-
cainamide administered intravenously versus orally in 6 of
18 patients in group 2 (p = 0.02) but in none of the 15
patients in group I (Fig. I).
Effective serum concentration in group 2 (Table
I B). Regardless of the route of administration, the effective
procainamide concentration was greater than the ineffective
concentration in five of six patients with a discordant re-
sponse to programmed stimulation. In four patients, in-
creased serum concentration of procainamide after oral
administration was effective in preventing induction of the
tachycardia . In these four patients, the effective serum con-
centration ranged from 12.1 to 21.0 fLg/ml (mean 15.5 :±:
3.9). The meanincreasein theeffectiveserum concentration
after orally administered procainamide compared with the
intravenous regimen was 5.7 :±: 0.2 fLglml (range 4.7 to
5.9). One patient (Patient 26) had a much higher serum
procainamide concentration after intravenously adminis-
teredprocainamidecomparedwith that achievedorally. This
increase in concentration proved effective in preventingar-
rhythmia induction. Finally, anotherpatient (Patient 29) had
an effective procainamide concentration after the oral
administration of the agent that was less than the ineffective
serum concentration after intravenously administered pro-
cainamide. Of note, in this patient there was a more marked
increase in ventricular refractoriness after oral than after
intravenous administration of procainamide, and ventricular
capture with short stimulus coupling intervals that initiated
ventricular fibrillation after intravenous procainamide was
not achieved.
Mode of induction (Table 1). After oral administration
of procainamide, sustained ventricular arrhythmias became
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harder to initiate or noninducible in 15 patients, there was cainamide, sustained ventricular arrhythmias became harder
no change in the ease of arrhythmia inducibility in 10 pa- to initiate in 14 patients, there was no chanage in the ease
tients and the arrhythmia became easier to initiate in 8 pa- of inducibility in 13 patients and the tachyarrhythmia be-
tients. Similarly, after intravenous administration of pro- came easier to initiate in 6 patients. In group I, ease of
Table 1. Electrophysiologic Effects of Oral and Intravenous Procainamidc
Oral Administration Intravenous Administration
Response to ~CL of Response to
Patient Dose PR [1 NAPA [1 AYRPt PYS (ease of YTII PR [ 1 NAPA [ 1 ~YRPt PYS (ease of ~CL of YTII
No . (g) (~g/ml) ( ~glml) (ms) YT induction) (ms) ( ~g/m l) (~g/ml) (ms) YT induction) (rns)
A. Group I: Concordant Serum Concentrati ons§
I 1.0 q4h 7.9 5.3 + 10 Nl(H) * 5.7 0.3 + 10 NI(H) *
2 1.0 q4h 11.2 4 .8 + 50 Nl(H) * 11.9 1.6 + 50 NI(H) *
3 1.0 q6M 7.5 8.0 + 40 NI(H) * 6.8 1.3 + 50 NI(H) *
4 1.0 q4h 12.3 5.4 + 50 I(E) + 70 12. 1 1.0 + 40 I(E) + 60
5 1.0 q6h :j: 7 .6 9 .3 + 30 NI(H) * 9 .5 2.7 + 30 NI(H) *
6 1.0 q4h 7 .8 4 .9 + 30 l(E ) + 60 9.9 1.5 + 30 I(NC) + 10
7 0 .75 q4h 7.9 11.8 - 20 I(NC) + 30 7. 1 1.1 - 10 I(NC) +60
8 1.0 q4h 7.4 4 .6 + 30 I(E) * 10.0 1.4 + 20 I(NC)
9 1.0 q4h 7.1 6.5 NR I(E) * 6 . 1 0.5 NR I(E)
10 1.25 q4h 10 .6 6.4 + 20 I(NC) * 10.5 1.1 + 30 I(E) *
II 1.0 q6h :j: 5 .5 1.7 + 30 I(NC) + 60 6.7 0.3 NR l(E) + 80
12 1.5 q4h 15.7 7.0 + 40 I(E) 12.8 0 .8 + 60 I(NC) *
13 0 .50 q4h 8.8 11.8 + 40 NI(H) * 8.6 0. 9 + 40 NI(H) *
14 1.0 q4h 8.9 5 .3 + 40 l(H) + 90 6 .9 0.9 + 40 I(NC) + 50
15 0 .50 q4h 5.6 3.6 + 20 l( NC) + 50 4 .0 0.4 0 I(H) + 50
Mean value 8.8 6.2 + 29 +60 8.6 1.0 + 28 + 52
± SD 2.7 2.8 19 20 2.6 0 .6 23 23
B. Group 2: Discordant Serum Concentrations§
16 1.0 q4h 15.4 7.2 + 30 NI(H) 9 .8 1.1 + 10 l(H) + 80
17 1.0 q4h 15.3 6.2 0 I(NC) + 70 8.8 0.4 + 20 1(1-0 + 30
18 0 .5 q4h 2.2 3.9 + 20 I(E) + 90 7.4 0 .6 + 20 l(H) *
19 1.5 q6h t 21.0 8.9 + 30 NI(H) 15.1 0.2 + 30 l(NC) *
20 1.0 q4h 13.2 4 .7 + 50 I(E) 4 .3 0.7 0 I(NC) *
21 1.0 q3h 20.2 9.0 NR I(NC) * 8.5 0.7 NR I(E) *
22 0 .75 q4h 11.9 21. 9 NR I(E) + 130 7.2 0.2 - 20 I(NC) + 100
23 1.0 q4h 15.4 13.4 NR I(H) + 40 9. 6 1.5 NR I(H) + 80
24 1.0 q4h 13.5 18.9 + 70 l(NC ) + 30 6.4 1.0 + 50 I(NC) 5
25 0 .75 q4h 12.8 17.8 NR I(H) 9.0 1.6 NR I(H)
26 2.0 q4h 23.0 9.3 + 60 I(NC) + 10 30.8 1.0 + 60 NI(H) *
27 1.0 q4h 13.9 16 .6 + 30 NI(H) * 6.9 0 .9 + 20 NI(H)
28 1.25 q4h 19.2 18.7 + 30 NI(H) 6.0 2.0 + 10 NI(H)
29 0 .75 q4h 5.6 3.9 + 30 NI(H) 9.2 1.3 + 10 I(NC) *
30 1.0 q4h 9 . 1 5. 1 + 10 I(NC) + 50 5.4 0.4 0 I(NC) *
3 1 1.0 q4h 12.1 8.9 + 50 NI(H) * 6.6 0.4 + 20 l(NC) + 80
32 1.0 q4h 16.7 8.2 + 30 l(NC) + 70 11.9 1.5 + 10 I(NC) + 50
33 1.5 q6h:j: 13.6 10.7 + 20 NI(H) * 7.9 1.1 + 20 I(E) + 100
Mean value 14.1 10 .7 + 33 + 68 9.5 0 .9 + 20 + 5 1
± SD 5.2 5.7 19 39 5.9 0 .5 17 4 1
*Indicates dif ferent configurations of induced ventricular tachycardia or no inducible ventricular tachycardia; t change in ventricular refractoriness
compared with that determined during base line study; :j:procainamide administered as slow release capsule (PROCAN ®SR) every 6 hours; §concordant
serum concentrations < 3 mg/dl dif ference in serum concentrations of procainamide (see text) ; IIchange in cycle length of ventricular tachycardia compared
with that determined durin g baseline study. E = change in mode of induction compared with baseline study to one requiring fewer extrastimuli (see
text) ; H = change in mode of induction compared with baseline study to one requiring more extrastimuli (see text) ; I = inducible sustained ventricular
arrhythmia: NC = no change in number of extrastimuli requi red to initiate YT compared with baseline study (see text); NI = no inducible sustained
ventricular arrhythmia; NR = not reached because of induction of ventr icular tachycardia with single extrastimuli or incessa nt ventricular tachycardia
durin g baseline study; NAPA [ 1 = serum N-acetylprocainamide concentration; PR [ 1 = serum procainamide concentration; PYS = programm ed
ventricular stimulation; SD = standard dev iation ; ACL of YT = change in cycle length of ventricular tachycardia; AYRP = change in ventricular
refractory period ; YT = ventricular tachycardia .
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Figure 1. The electrophysiologic response with respect to induc-
ibility (Of ventricular arrhythmias in patients with a similar serum
procainamide concentration (group I) is compared with that in
patient> with a dissimilar procainamide concentration (group 2).
All 15 patients in group 1 had the same response to programmed
stimulation, whereas6 of the 18patients in group 2 had a different
response. EP = electrophysiologic; p = probability value.
indue ibility with respect to the mode of induction compared
with the baseline study was the same after intravenous and
oral procainamide in 8 of the 15 patients. In group 2, ease
of inducibility compared with the baseline state was the
same after intravenous and oral procainamide in 8 of the
18 pauents. Only one of the five patients in group 2 whose
arrhythmia subsequently became non inducible only during
oral procainamide therapy had a more difficult initiation of
the arrhythmia after intravenous therapy when compared
with the baseline study. Serum procainamide concentration
during the 14 stimulation trials in which ventricular tachy-
cardia became easier to initiate was 9.2 ± 3.7 Mg/ml com-
pared with 11.0 ± 4.3 Mg/ml (p = NS) during the 29 trials
in which ventricular tachycardia became more difficult to
initiate.
Effect on ventricular tachycardia cycle length. Eleven
patients had ventricular tachycardia with the same config-
uration induced during the baseline state and after intra-
venous and oral procainamide (Fig. 2). In these II patients,
the cycle length of the morphologically similar ventricular
tachycardia increased by a mean of 63 ± 29 ms after oral
administration of procainamide and by 52 ± 31 ms (p =
NS) after intravenous administration of procainamide. The
trend toward a greater increase in tachycardia cycle length
after oral administration paralleled a modest increase in the
mean serum concentration of procainamide after its oral
administration, 11.0 ± 4.0 Mg/ml, compared with a con-
centration of 8.2 Mg/ml (p < 0.01) after intravenous
admin istration.
Effect on ventricular refractoriness. Ventricular re-
fractoriness increased nearly uniformly after procainamide
administration. In group I patients, ventricular refractori-
ness increased by a mean of 29 ± 19 ms after oral admin-
PO
11.0t4.0 P< .01
9.2±6.5
AVT CL
(ms)
IV
PROCAINAMIDE [,J 8.2 t2.5
NAPA ['J 0.9 sos
Figure 2. Effect of procainamide and its route of administration
on the cycle length (Cl.) of ventricular tachycardia (VT) of the
sameconfiguration. The mean increase in tachycardiacycle length
after intravenous (IV) procainamide was 52 ± 30 ms and 63 ±
27 ms after oral (PO) administration (see text). NAPA [ ] = N-
acetylprocainamide serum concentrations; NS = not significant;
p = probability.
istration of procainamide and by a mean of 28 ± 23 ms
after intravenous administration of procainamide (p = NS).
In group 2 patients, ventricular refractoriness increased by
a mean of 33 ± 19 ms after oral administration and by a
mean of 20 ± 17 rns after intravenous administration (p <
0.01) and paralleled the difference in mean serum procain-
amide concentrations (Table I). The degree of increase in
ventricular refractoriness was more closely correlated with
serum concentrations after intravenous administration of
procainamide (r = 0.53, P < 0.05) than after oral admin-
istration of procainamide (r = 0.31, P = 0.1) (Fig. 3).
Effect ofN-acetylprocainamide concentrations. In pa-
tients in group I, despite differences in serum N-acetylpro-
cainamide concentration, the effect 011 inducibility of the
ventricular arrhythmias and ventricular refractoriness was
similar after intravenous and oral procainamide administra-
tion. The concentration of N-acetylprocainamide in the II
patients in whom the sustained ventricular arrhythmias was
no longer inducible after oral procainamide did not differ
significantly from that in those patients in whom the ven-
tricular arrhythmia remained inducible (9.5 ± 4.5 versus
8.4 ± 5.4 Mg/ml, p = NS). Finally, the addition of the
N-acetylprocainamide concentration (r = 0.28, P = NS)
or one-half of it (r = 0.33, P = NS) to the serum pro-
cainamide concentration was not better correlated with the
increase in ventricular refractoriness than with the procain-
amide concentration alone.
p = 0.02
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Figure 3. Relation of serum procainam ide concentration to the
change in ventricular refractory periods (VRPj after intravenous
(panel Aj and oral (panel B) procainamide administration. Change
in refractoriness was better correlated with serum procainam-
ide concentration achieved after intravenous procainamide
admini stration .
Discussion
Effect on preventing induction of ventricular arrhyth-
mias. Programmed electrical stimulation had been used to
evaluate efficacy of antiarrhythmic agents (5-7). For type
1 antiarrhythmic agents including procainarnide, prevention
of inducibility of sustained ventricular arrhythmia has pre-
dicted clinical efficacy (5-7,9,10). Prevention of induci-
bility with acute intravenous procainamide administration
range s from 14 to 48%, and differences are believed to be
related to discrepancies in dosing and serum concentrations
(5-7,10,11 ). We found a 24% success rate in prevention
of induction of sustained ventricular arrhythmia using short-
term intravenous administration. Of note , a vigorou s stim-
ulation protocol that included triple extrastimuli was used
during this study . The mean effective serum procainamide
concentration after intravenous procainamide admini stration
was 10.8 ± 8.3 p,g/ml. When oral testing was also assessed ,
the total percent success in prevention of induction increased
to 39%. The mean effecti ve serum concentration on the oral
regimen of procainamide was 12.0 ± 4.9 p,g/ml, a con-
centration that is slightly greater than the 9. 1 ± 3.4 p,g/ml
reported by Myerburg et at. (/2) to prevent spontaneous
ventricular tachycardia.
Importantly, prevention of inducibility using short-term
intravenous drug testing correlated 100% with the results
of programmed stimulation on the oral regimen when similar
serum procainamide concentrations, within 3 p,g/ml, were
achieved. In fact, efficacy in preventing induct ion of the
ventricular arrhythmia of an oral regimen when the intra-
venous regimen failed could be demon strated with one ex-
ception-only when the serum concentration increased by
a mean of 5.7 ± 0.2 from 9 .8 to 15.5 p,g/mt. The reason
for the exception (Patient 29) to the requirement for an
increase in serum concentration of procainamide after oral
procainamide cannot be definitively explained. A more marked
increase in ventricular refractoriness despite the lesser serum
concentration after oral procainamide may have contributed
to the inability to initiate the arrhythmia by preventing cap-
ture of the short coupled extrastimul i that had initiated the
arrhythmia after intravenous procainamide.
Using our standard intravenous dosing regimen of 15
mg/kg or approximately I g, serum procainamide levels
between 6 and 12 J,Lg/ml can be routinely achieved. If the
arrhythmia is not inducible after intravenous administration
and similar trough procain amide concentrations can be
achieved during oral therap y. then repeat programmed stim-
ulation appears unnecessary . If the arrhythmia is still in-
ducible after the intravenous administration of procaina-
rnide, then repeat testing during oral therapy appears warranted
only if serum concentrations at least greater than 3 p,g/ml
can be achieved .
In view of our data , one may question the need for in-
travenou s administration and subsequent electrophysiologic
testing since the oral procainamide success rate was higher
than the intravenous rate . However , the ease and safety of
intravenous administration of procainamide allow for short-
term electrophysiologic testing to assess drug efficacy on
the same day as the control study . This may eliminate the
need to perform repeat venous catheterization and shorten
the hospital stay.
Effect on ease of inducibility. As has been previously
reported (11,13), we found that in approximately 20% of
lACC \,,1. 4, No.6
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the patients, ventricular tachycardia after short-term intra-
venous administration of procainamide could be more easily
induced than during the baseline state, In addition, we found
parallel results in a similar percent of patients after the oral
administration of procainamide. Although a trend toward
greater serum concentration of procainamide existed when
ventricular tachcyardia became more difficult to initiate, a
significant association between serum procainamide con-
centrations and ease of inducibility was not observed. In
addition, patients who required fewer extrastimuli after in-
travenous therapy to initiate their arrhythmia did not nec-
essarily require fewer extrastimuli after oral procainamide
therapy and, in fact, in one patient who required fewer
extrastimuli after intravenous therapy, the arrhythmia be-
came noninducible after oral therapy. Thus, except for total
abolition of inducible ventricular arrhythmia, change in the
ease of inducibility after intravenous procainamide therapy
did not clearly identify those patients more or less likely to
have induction of their arrhythmia prevented by oral
procainamide.
Effect on tachycardia cycle length. Wellens et al. (II)
observed a mean increase of 87 ± 51 ms in the cycle length
of the ventricular tachycardia induced after intravenous
administration of procainamide at a dose of 10 mg/kg. Kang
et al (13) noted a mean increase of 52 ms in induced
tachycardia cycle length in eight patients with similar epi-
sodes of tachycardias, seven of whom had only nonsustained
ventncular tachycardia. The increase in tachycardia cycle
length occurred after the intravenous infusion of 750 mg of
procainamide. We found similar changes in tachycardia cycle
length after both intravenous and oral procainamide (Fig.
2). Of note, in approximately 60% of patients, a morpho-
logically different ventricular tachycardia was initiated after
either oral or intravenous procainamide. This effect on ep-
isodes of induced tachycardia may be due to alterations in
wave fronts of ventricular activation or changes in exit sites
from reentrant tachycardia circuits related to the effect of
procainamide on conduction and refractoriness.
Effect on ventricular refractoriness. Similar to pre-
vious reports (11,14), ventricular refractoriness after intra-
venous administration increased by a mean of 20 to 28 ms.
In addition, we found a similar increase in ventricular re-
fractoriness after either intravenous or oral administration
of procainamide when serum concentrations were similar
(group I). We noted a closer correlation of refractory period
change with serum concentration after intravenous admin-
istration of procainamide than after oral administration of
procainamide (Fig. 2). This may, in part, be due to minor
differences in refractory period determinations inherent in
catheter measurements performed on different days as was
the case for the repeat measurements after oral procainamide
administration.
Effects of N-acetylprocainamide. N-acetylprocaina-
mide concentrations between 10 and 30 iLg/ml have been
reported to be associated with a significant reduction in
frequency of ventricular premature depolarizations and in
two patients effective suppression of induced sustained ven-
tricular tachycardia (15-17). Karlsson and Sonnhag (18)
reported that N-acetylprocainamide has half the electro-
physiologic potency of procainamide, and Elson et al. (19)
reported that N-acetylprocainamide has half the electro-
acetylprocainamide that we observed did not have signifi-
cant antiarrhythmic potency with respect to sustained ar-
rhythmia induction and probably contributed little to the
electrophysiologic effects of procainamide. No patient in
group I with similar serum procainamide concentrations had
a different response to programmed stimulation with respect
to inducibility of the ventricular arrhythmia after oral pro-
cainamide despite having a greater serum N-acetylprocain-
amide concentration. In addition, we could not improve the
correlation between the serum procainamide level and change
in ventricular refractoriness by adding one-half or all the
total N-acetylprocainamide concentration to the serum pro-
cainamide concentration (18,19).
Limitations of the study. Because of the design of this
study in which the oral procainamide dosage was selected
to achieve a level at least equal to that achieved intrave-
nously or that which was tolerated without side effects, there
were only three patients (Table IB) in whom the serum
concentration on the oral regimen of procainamide was less
than that after its intravenous administration. Thus, we are
unable to comment on the frequency or possible significance
of a lower serum concentration after oral procainamide being
more effective in preventing the induction of ventricular
tachycardia.
Conclusions. In the range of dosing and serum pro-
cainamide concentrations observed, we found that intra-
venous procainamide closely predicts the electrophysiologic
effects of oral procainamide when similar serum concen-
trations are achieved. Therefore, repeat electrophysiologic
testing during oral administration of procainamide when
intravenous administration prevents induction of ventricular
arrhythmia is not necessary provided that a similar concen-
tration can be achieved. In addition, N-acetylprocainamide
contributes little to the electrophysiologic effects of pro-
cainamide at the serum N-acetylprocainamide concentra-
tions noted. Finally, if intravenous procainamide fails to
prevent tachyarrhythmia induction, repeat electrophysio-
logic testing during oral procainamide administration to de-
termine antiarrhythmic efficacy appears to be indicated only
if an increased serum procainamide concentration, at least
greater than 3 iLg/ml, can be achieved.
We thank Linda Pentz for her skillful preparation of this manuscript,
Belinda Flores and Darlene Pembrook-Rogers for their assistance in data
collection, and the technicians and nurses of the electrophysiology laboratory.
1254 MARCHLINSKI ET AL
EFFECTS OF [NTRA VENOUS AND ORAL PROCA[NAMIDE
rxcc Vol. 4. No.6
December [984:1247-54
References
1. Kayden HJ, Steele JM, Clark LC, Brodie BB. The use of procainamide
in cardiac arrhythmias. Circulation 1951;4:13-22.
2. Bigger TJ, Heissenbuttel RA. The use of procainamide and lidocaine
in the treatment of cardiac arrhythmias. Prog Cardiovasc Dis
1969;11:515-34.
3. Bellet S. Diagnosis and management. In: Essentials of Cardiac Ar-
rhythmias. Philadelphia: WB Saunders, 1972:358.
4. Kosowsky BD, Taylor J, Lown B, Ritchie RF. Long-term use of
procainamide following acute myocardial infarction. Circulation
1973;47:1204-10.
5. Engel TR, Gonzalez A del C, Meister SG, Frankel WS. Effect of
procainamide on induced ventricular tachycardia. Clin Pharmacol Ther
1978;24:3:274-82.
6. Horowitz LN, Josephson ME, Farshidi A, Spielman SR, Michelson
EL, Greenspan AM. Recurrent sustained ventricular tachycardia. 3.
Role of the electrophysiologic study in selection of antiarrhythmic
regimens. Circulation 1978;58:986-97.
7. Mason JW, Winkle RA. Electrode catheter arrhythmia induction in
the selection and assessment of antiarrhythmic drug therapy for re-
current ventricular tachycardia. Circulation 1978;58:971-85.
8. Rocco RM, Abbott DC, Giese JRW, Kerger LB. Analysis of pro-
cainamide and N-acetyl procainamide in plasma or serum by high
performance liquid chromatography. Clin Chern 1977;23:705-8.
9. Waxman HL, Buxton AE, Sadowski LM, Josephson ME. The re-
sponse to procainamide during e1ectrophysiologic study for sustained
ventricular tachyarrhythmias predicts the response to other medication.
Circulation 1983;67:30-7.
10. Greenspan AM, Horowitz LN, Spielman SR, Josephson ME. Large
dose procainamide therapy for ventricular tachyarrhythmia. Am J Car-
diol 1980;46:453-61.
11. Wellens HJJ, Bar FW, Lie KI, Duren DR, Dohmen HJ. Effect of
procainamide, propranolol and verapamil on mechanism of tachy-
cardia in patients with chronic recurrent ventricular tachycardia. Am
J Cardiol 1977;40:479-85.
12. Myerburg RF, Kessler KM, Kiem I, et al. Relationship between plasma
levels of procainamide, suppression of premature ventricular com-
plexes and prevention of recurrent ventricular tachycardia. Circulation
1981;64;280-9.
13. Kang PS, Gomes JAC, EI Sherif N. Procainamide in the induction
and perpetuation of ventricular tachycardia in man. PACE 1982;
5:311-22.
14. Josephson ME, Caracta AR, Ricciutti MA, Lau SH, Damato AN.
Electrophysiologic properties of procainamide in man. Am J Cardiol
1974;33:596-603.
15. Sung RJ, Juma Z, Saksena 5. Electrophysiologic properties and an-
tiarrhythmic mechanisms of intravenous N-acetyl procainamide in pa-
tients with ventricular dysrrhythmias. Am Heart J 1983;105:811-9.
16. Kluger J, Drayer D, Reidenberg M, et al. The clinical pharmacology
and antiarrhythmic efficacy of acetyl procainamide in patients with
arrhythmias. Am J Cardiol 1980;45:1250-6.
17. Roden DM, Reele 5B, Higgins 5B, et al. Antiarrhythmic efficacy,
pharmacokinetics and safety of N-acetyl procainamide in human sub-
jects-comparison with procainamide. Am J Cardiol 1980;46:463-8.
18. Karlsson E, Sonnhag C. Comparative evaluation of procainamide and
its main metabolite, N-acetyl procainamide, in the acute treatment of
ventricular arrhythmias (abstr). Br J Clin Pharmacol 1979;4:632P.
19. Elson J, Strong JM, Lee WK, Atkinson AJ. Antiarrhythmic potency
of N-acetyl procainamide. Clin Pharmacol Ther 1975;17:134-40.
